-
1
-
-
33748946748
-
-
* De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités é tiopathogéniques et thérapeutiques. Rev Med Suisse 2006;2:1893-900.
-
* De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités é tiopathogéniques et thérapeutiques. Rev Med Suisse 2006;2:1893-900.
-
-
-
-
2
-
-
10744221639
-
-
** Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
-
** Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
-
-
-
-
3
-
-
0037453063
-
Glitazones and heart failure: Critical appraisal for the clinician
-
Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart failure: Critical appraisal for the clinician. Circulation 2003;107:1350-4.
-
(2003)
Circulation
, vol.107
, pp. 1350-1354
-
-
Wang, C.H.1
Weisel, R.D.2
Liu, P.P.3
Fedak, P.W.4
Verma, S.5
-
4
-
-
19244365650
-
Thiazolidinediones
-
Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
-
(2004)
N Engl J Med
, vol.351
, pp. 1106-1118
-
-
Yki-Järvinen, H.1
-
5
-
-
34247122261
-
Fluid retention with thiazolidinediones. Does the mechanism influence the outcome ?
-
Lindenfeld J, Masoudi FA. Fluid retention with thiazolidinediones. Does the mechanism influence the outcome ? J Am Coll Cardiol 2007;49:1705-7.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1705-1707
-
-
Lindenfeld, J.1
Masoudi, F.A.2
-
6
-
-
26244453309
-
-
** Dormandy J, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.
-
** Dormandy J, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.
-
-
-
-
7
-
-
33845405222
-
ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med
-
** Kahn SE, Haffner SM, Heise MA, et al for the
-
** Kahn SE, Haffner SM, Heise MA, et al for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
-
(2006)
, vol.355
, pp. 2427-2443
-
-
-
8
-
-
33748748206
-
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
-
** The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators
-
** The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-105.
-
(2006)
Lancet
, vol.368
, pp. 1096-1105
-
-
-
9
-
-
26244444319
-
The PROactive study: Some answers, many questions
-
Yki-Járvinen H. The PROactive study: Some answers, many questions. Lancet 2005;366:1241-2.
-
(2005)
Lancet
, vol.366
, pp. 1241-1242
-
-
Yki-Járvinen, H.1
-
10
-
-
33846222754
-
Adjudication of serious heart failure in patients from PROactive
-
Ryden L, Thrainsdottir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet 2007;369:189-90.
-
(2007)
Lancet
, vol.369
, pp. 189-190
-
-
Ryden, L.1
Thrainsdottir, I.2
Swedberg, K.3
-
11
-
-
33847675510
-
on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction
-
Erdmann E, Dormandy JA, Charbonnel B et al, on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol 2007;49:1772-80.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1772-1780
-
-
Erdmann, E.1
Dormandy, J.A.2
Charbonnel, B.3
-
12
-
-
33947539408
-
PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
-
Wilcox R, Bousser MG, Betteridge DJ, et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38: 865-73.
-
(2007)
Stroke
, vol.38
, pp. 865-873
-
-
Wilcox, R.1
Bousser, M.G.2
Betteridge, D.J.3
-
13
-
-
0242332284
-
Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. A retrospective cohort study
-
Delea TE, Edetsberg JS, Hagiwara M, Oster G, Philips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. A retrospective cohort study. Diabetes Care 2003;26:2983-9.
-
(2003)
Diabetes Care
, vol.26
, pp. 2983-2989
-
-
Delea, T.E.1
Edetsberg, J.S.2
Hagiwara, M.3
Oster, G.4
Philips, L.S.5
-
14
-
-
21544465051
-
Insulin-sensitizing anti hyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project
-
Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing anti hyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. Diabetes Care 2005;28:1680-9.
-
(2005)
Diabetes Care
, vol.28
, pp. 1680-1689
-
-
Inzucchi, S.E.1
Masoudi, F.A.2
Wang, Y.3
-
15
-
-
22644438570
-
Pioglitazone initiation and subsequent hospitalization for congestive heart failure
-
Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22:986-93.
-
(2005)
Diabet Med
, vol.22
, pp. 986-993
-
-
Karter, A.J.1
Ahmed, A.T.2
Liu, J.3
Moffet, H.H.4
Parker, M.M.5
-
16
-
-
13444272949
-
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study
-
Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation 2005;11:583-90.
-
(2005)
Circulation
, vol.11
, pp. 583-590
-
-
Masoudi, F.A.1
Inzucchi, S.E.2
Wang, Y.3
-
17
-
-
33746588255
-
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
-
(2006)
Diabetes Care
, vol.29
, pp. 1963-1972
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
18
-
-
37649032370
-
Pioglitazone for type 2 diabetes mellitus
-
CD006060
-
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006; Issue 4:CD006060.
-
(2006)
Cochrane Database of Systematic Reviews
, Issue.4
-
-
Richter, B.1
Bandeira-Echtler, E.2
Bergerhoff, K.3
Clar, C.4
Ebrahim, S.H.5
-
19
-
-
33947134267
-
-
* Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract 2006;76:279-89.
-
* Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract 2006;76:279-89.
-
-
-
-
20
-
-
34548776617
-
-
De Flines J, Scheen AJ. Pioglitazone, oedema and congestive heart failure: A meta-analysis of randomised controlled trials (abstract). Diabetologia 2007;50 (Suppl. 1): in press.
-
De Flines J, Scheen AJ. Pioglitazone, oedema and congestive heart failure: A meta-analysis of randomised controlled trials (abstract). Diabetologia 2007;50 (Suppl. 1): in press.
-
-
-
-
21
-
-
23844472901
-
Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption
-
Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-6.
-
(2005)
Nat Med
, vol.11
, pp. 861-866
-
-
Guan, Y.1
Hao, C.2
Cha, D.R.3
-
22
-
-
4944262294
-
Combined thiazolidinedione-insulin therapy. Should we be concerned about safety?
-
Scheen AJ. Combined thiazolidinedione-insulin therapy. Should we be concerned about safety? Drug Safety 2004;27:841-56.
-
(2004)
Drug Safety
, vol.27
, pp. 841-856
-
-
Scheen, A.J.1
-
23
-
-
0037393015
-
Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure
-
Tang WHW, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41:1394-8.
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 1394-1398
-
-
Tang, W.H.W.1
Francis, G.S.2
Hoogwerf, B.J.3
Young, J.B.4
-
24
-
-
7044253431
-
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
-
Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.
-
(2004)
Arch Intern Med
, vol.164
, pp. 2097-2104
-
-
Chiquette, E.1
Ramirez, G.2
DeFronzo, R.3
-
25
-
-
33846657175
-
Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: A meta-analysis
-
Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: A meta-analysis. Diabetes Care 2007;30:384-8.
-
(2007)
Diabetes Care
, vol.30
, pp. 384-388
-
-
Riche, D.M.1
Valderrama, R.2
Henyan, N.N.3
-
26
-
-
34250212715
-
-
* Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
-
* Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
-
-
-
-
28
-
-
24944569269
-
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol
-
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia 2005;48:1726-35.
-
(2005)
Diabetologia
, vol.48
, pp. 1726-1735
-
-
Home, P.D.1
Pocock, S.J.2
Beck-Nielsen, H.3
-
29
-
-
34250865768
-
-
* Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
-
* Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
-
-
-
-
30
-
-
34250826679
-
Rosiglitazone and cardiotoxicity - Weighing the evidence
-
Nathan DM. Rosiglitazone and cardiotoxicity - Weighing the evidence. N Engl J Med 2007;357:64-6.
-
(2007)
N Engl J Med
, vol.357
, pp. 64-66
-
-
Nathan, D.M.1
|